Skip to main content
Premium Trial:

Request an Annual Quote

Fluidigm Biomark X

Fluidigm has launched BioMark X, the latest generation of its Biomark microfluidic real-time PCR platform. Biomark X integrates the company's Juno microfluidic sample preparation platform with the company's current BioMark HD instrument into a single sample-to-answer platform, the company said. The integrated system can be used for a variety of applications including genotyping, sample ID, strain ID, conservation biology, personal genomics, gene expression, pathogen detection, pharmacogenomics assays, and transplant prognostics, according to Fluidigm. The platform also supports development and creation of custom assays, and the ability to scale the number of targets based on need. According to the company's website, BioMark X supports the company's 48.48 Dynamic Array Integrated Fluidic Circuit (IFC), enabling 2,304 reactions using 48 samples and assays; and the 96.96 Dynamic Array IFC, enabling 9,216 reactions using 96 samples and assays.

Fluidigm said the platform is in a phased launch with deliveries expected to commence in the first quarter of 2022.

The Scan

Close Panel Vote on Califf Nomination

The New York Times reports there was a close committee vote to advance the nomination of Robert Califf to lead the US Food and Drug Administration to the full Senate.

Task Force Reports on Scientific Integrity

Nature News writes that that a new task force report recommends that the US establish a cross-agency scientific integrity council.

Across the Hall

Genetic testing, closed-circuit cameras, and more show how a traveler, without any contact, infected others at a New Zealand quarantine facility, CNN reports.

Science Paper Examines Influence of Chromatin Modifications on Obsessive-Compulsive Disorder

In Science this week: genes regulating chromatin modification may contribute to OCD risk.